Application of new hypoglycemic drugs of the three most common types of maturity-onset diabetes of the young

VernacularTitle:新型降糖药物在三种常见青少年的成年起病型糖尿病亚型上的应用
Author: Qianwen DUAN ; Huifang PENG ; Yujin MA ; Hongwei JIANG
From: Chinese Journal of Endocrinology and Metabolism 2021;37(3):262-266
CountryChina
Language:Chinese
Abstract: Maturity-onset diabetes of the young (MODY)is a heterogeneous monogenic diabetes, in which MODY1, MODY2, and MODY3 are the most common subtypes. In recent years, new hypoglycemic drugs such as glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i), sodium-glucose co-transporter 2 inhibitors (SGLT2i), and glucokinase activators (GKA)have made good progress in the treatment of diabetes. Based on the latest basic and clinical evidence, the article reviews the pathogenesis, clinical features, diagnosis and treatment progress of new hypoglycemic drugs of the above three types of MODY, aiming to develop safer and more effective new ways for the diagnosis and treatment of MODY.